Trial Profile
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 16 Feb 2024 Status changed from active, no longer recruiting to completed.
- 15 Jul 2022 Results published in the Journal of Clinical Investigation
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology